Pacira BioSciences (PCRX) Total Liabilities (2010 - 2026)

Pacira BioSciences' Total Liabilities history runs 17 years deep, the most recent figure standing at $554.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 29.63% year-over-year to $554.6 million in Q1 2026; TTM through Mar 2026 was $554.6 million, a 29.63% decrease from a year earlier, with the FY2025 full-year figure at $571.8 million, down 26.23% from the prior year.
• Total Liabilities retreated to $554.6 million in Q1 2026 per PCRX's latest filing, from $571.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.2 billion in Q1 2022 and bottomed at $554.6 million in Q1 2026.
• The 5-year median for Total Liabilities is $767.5 million (2024), against an average of $776.3 million.
• Across the five-year window, Total Liabilities jumped 85.62% in 2022 and tumbled 36.09% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $906.2 million in 2022, then fell by 22.28% to $704.3 million in 2023, then advanced by 10.07% to $775.2 million in 2024, then slipped by 26.23% to $571.8 million in 2025, then dropped by 3.0% to $554.6 million in 2026.
• Per Business Quant, the three latest PCRX Total Liabilities figures stand at $554.6 million (Q1 2026), $571.8 million (Q4 2025), and $570.4 million (Q3 2025).